JW Life Science Explores Entry into Chinese Infusion Market

[Asia Economy Reporter Cho Hyun-ui] JW Life Science announced on the 8th that it is preparing to enter the Chinese nutritional infusion market.

JW Life Science was selected last month for the "Pharmaceutical Industry Full-Cycle Global Expansion Support Project" organized by the Korea Health Industry Development Institute. Accordingly, 50% of the project cost will be subsidized.

JW Life Science was finally selected for the project in April and completed an on-site inspection of domestic production facilities over approximately seven months through a local consulting firm. They prepared to enter the Chinese nutritional infusion market by preemptively confirming the requirements of Chinese companies to minimize trial and error during the approval process.

The company is currently preparing additional materials to meet the requirements of the Chinese market. Since the Chinese market presents stringent standards in the CMC (Chemistry, Manufacturing, and Controls) field, they plan to continue focusing on supplementing CMC-related materials based on local consulting.

In October, JW Life Science signed a technology export and finished product supply contract for the comprehensive nutritional infusion product "Winnerf" with Shandong Luoxin through its holding company JW Holdings. Utilizing the results of the current local consulting, the goal is to successfully establish Winnerf in the Chinese nutritional infusion market in the future.

A JW Life Science official stated, "The Chinese pharmaceutical market has many unique regulations, making it a very challenging region to enter compared to other countries, so local consulting is essential. Recently, by signing the technology export and finished product supply contracts for Winnerf, we have opened the door to the Chinese market, and we will strive to achieve results quickly through thorough preparation."

This content was produced with the assistance of AI translation services.